FOXO1 fusion status aids paediatric local rhabdomyosarcoma risk assessment
Considering FOXO1 fusion status improves the risk assessment of children with localised rhabdomyosarcoma, suggest study findings published in Cancer.
Apitegromab shows motor function benefits in patients with SMA
Apitegromab improves motor function in patients with later-onset spinal muscular atrophy, show the results of the phase 2 TOPAZ study.
Home insulin pump use feasible for hospitalised children with type 1 diabetes
For children with type 1 diabetes who are admitted to hospital, continuing with a home insulin pump is feasible for the prevention of hyperglycemia and hypoglycemia, suggests research published in JAMA Network Open.
Autoimmune disease risk increased after surgical remission of Cushing’s disease
Patients with Cushing’s disease who achieve remission following surgery have an increased incidence of autoimmune disease, suggest findings published in the Annals of Internal Medicine in February 2024.
Mycophenolate mofetil withdrawal feasible in SLE patients with stable disease
Patients with systemic lupus erythematosus may be able to stop taking mycophenolate mofetil once their condition becomes stable without significantly increasing their risk for flare compared with continuing treatment, suggests an open-label, randomized controlled trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Tixagevimab plus cilgavimab offers COVID-19 protection for haematological cancer patients
Tixagevimab and cilgavimab immunoprophylaxis may help protect patients with haematological malignancies from COVID-19 infection and hospitalisation, suggests a research letter published in JAMA Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Blood immunoassay shows high diagnostic accuracy for Alzheimer’s disease pathology
A commercially available plasma phosphorylated (p)-tau217 immunoassay outperforms other biomarkers in accurately identifying biological Alzheimer’s disease, suggest findings from a study across three observational cohorts.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Bevacizumab addition to temozolomide chemotherapy may improve neuroblastoma response
Findings from the BEACON-Neuroblastoma trial suggest that adding bevacizumab to temozolomide-based chemotherapy may improve the objective response rate for children with high-risk, relapsed or refractory disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Add-on telitacicept improves clinical response in patients with active SLE
Telitacicept used in addition to standard therapy shows promising efficacy in Chinese patients with active systemic lupus erythematosus, suggests a phase 2b trial published in the Annals of the Rheumatic Diseases.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Cerliponase alfa treatment shows extended efficacy for CLN2 disease
Cerliponase alfa treatment slows the progression of neuronal ceroid lipofuscinosis type 2 disease for at least 5 years, shows an open-label extension study in The Lancet Neurology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
